Kim Straley
Agios Pharmaceuticals
9 Papers
69 Citations
Kim Straley is an academic researcher from Agios Pharmaceuticals. The author has contributed to research in topics: Mutant & Cellular differentiation. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.
Alan H. Shih,Cem Meydan,Kaitlyn Shank,Francine E. Garrett-Bakelman,Patrick S. Ward,Andrew M. Intlekofer,Abbas Nazir,Eytan M. Stein,Kristina M. Knapp,Jacob L. Glass,Jacob L. Glass,Jeremy Travins,Kim Straley,Camelia Gliser,Christopher E. Mason,Katharine E. Yen,Craig B. Thompson,Ari Melnick,Ross L. Levine +18 more
TL;DR: AMLs with mutations in TET2 or IDH2 are sensitive to epigenetic therapy through inhibition of DNA methyltransferase activity by 5-azacytidine or inhibition of mutant IDH1 through AG-221, and these inhibitors induce a differentiation response and can be used to inform mechanism-based combination therapy.
AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model
Katharine E. Yen,Fang Wang,Jeremy Travins,Yue Chen,Hua Yang,Kim Straley,Sung Choe,Marion Dorsch,David P. Schenkein,Samuel V. Agresta,Scott A. Biller,Michael Su +11 more
TL;DR: Preclinical in vivo evidence is provided that AG-221 may have clinical benefit for IDH2 mutant patients through the reduction of 2HG and the induction of blast differentiation and the onset of differentiation correlated with survival, whereas mice that died in the low dose groups failed to show signs of cellular differentiation.
31
AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo
Alan H. Shih,Kaitlyn Shank,Cem Meydan,Andrew M. Intlekofer,Patrick S. Ward,Craig B. Thompson,Ari Melnick,Jeremy Travins,Kim Straley,Camelia Gliser,Katherine Yen,Ross L. Levine +11 more
TL;DR: The in vivo efficacy of AG-221, a potent and selective mutant IDH2 inhibitor in early-phase clinical trials, is investigated in murine models of IDH 2-mutant leukemia, and aberrant methylation at many genes with a known role in hematopoietic proliferation and differentiation is reversed.
28
AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model
Cyril Quivoron,Cyril Quivoron,Cyril Quivoron,Muriel D. David,Muriel D. David,Muriel D. David,Kim Straley,Jeremy Travins,Hyeryun Kim,Yue Chen,Dongwei Zhu,Véronique Saada,Véronique Saada,Véronique Saada,Olivia Bawa,Paule Opolon,Mélanie Polrot,Jean-Baptiste Micol,Christophe Willekens,Olivier Bernard,Olivier Bernard,Olivier Bernard,Hua Yang,Sam Agresta,Stéphane de Botton,Stéphane de Botton,Stéphane de Botton,Katharine E. Yen,Virginie Penard-Lacronique +28 more
TL;DR: Test of the biological activity of AG-221, an oral, reversible and selective inhibitor of mutated IDH2 currently in phase I trials, developed primary human AML xenograft models and induced a burst of proliferation of human blasts followed by myeloid differentiation starting at day 20 in peripheral blood.
20
IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model
Katharine E. Yen,Lemieux Rene M,Janeta Popovici-Muller,Yue Chen,Hua Yang,Kim Straley,Sung Choe,Marion Dorsch,Samuel V. Agresta,David P. Schenkein,Scott A. Biller,Michael Su,Fang Wang +12 more
TL;DR: In these studies, AGI-14100 alone significantly decreased tumor burden in the peripheral blood after 1 month of continuous BID treatment, and in combination with a short-term, low-dose course of Ara-C, a decrease in the bone marrow tumor burden that was better than either treatment alone.
14